1-2 of 2
Keywords: Finerenone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy

Open Access
Subject Area:
Cardiovascular System , Nephrology
Justine Huart, François Jouret
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2025) 50 (1): 267–275.
https://doi.org/10.1159/000545286
Published Online: 17 March 2025
... system inhibitors (RAASi) and the recently approved type 2 Na + /glucose co-transporter inhibitors (SGLT2i) have significantly improved patient outcomes, residual risks remain unaddressed. Summary: This review explores (1) the mechanisms of action of finerenone, a novel non-steroidal mineralocorticoid...
View articletitled, Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy
Open the PDF for Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy in another window
Journal Articles

A Trial of Finerenone in a Patient with Primary Aldosteronism

Open Access
Subject Area:
Cardiovascular System , Nephrology
Sandra Karanović Štambuk
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2024) 49 (1): 839–842.
https://doi.org/10.1159/000541441
Published Online: 18 September 2024
... effects, including menstrual cycle disorders in women. Finerenone is a new, highly selective, nonsteroidal MRA with excellent side-effect profile, primarily intended to slow the progression of diabetic kidney disease and improve cardiovascular outcomes in these patients. No data are available so far...
View articletitled, A Trial of Finerenone in a Patient with Primary Aldosteronism
Open the PDF for A Trial of Finerenone in a Patient with Primary Aldosteronism in another window